Intravenous Lidocaine to Reduce ED50 for Propofol Administered Using Target Controlled Infusion (TCI) During Gastroscopy

• Status: Recruiting
• Trial end date: 2024-08-31
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this prospective, interventionnal clinical trial is to assess if intravenous administration of linisol reduce the ED50 of propofol when administered using Target Controlled Infusion (TCI) during gastroscopy in healthy patients (ASA 1 and 2 patients).

Prior to propofol sedation, participants will receive either an intravenous bolus of linisol (1.5 mg/kg) = treated group or placebo = control group.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Erasme University Hospital
• Treatments: Lidocaine; Pharmaceutical Solutions; Propofol

Criteria

Inclusion Criteria:

• Patients scheduled for gastroscopy under narcosis and who have signed the consent.

• ASA score: 1 and 2

• BMI between 18 and 30 kg/m2

Exclusion Criteria:

• Lidocaine allergy

• Anesthesia within the last 7 days

• Use of local anesthesia in the last 24 hours

• Rhythm disorder or HR <50

• Pregnant women and breastfeeding

• Participation in another clinical study in the last months

• Cannot understand VAS score or French

• Severe central nervous disease and mental illness.

• Obstructive sleep apnea (known or STOP BANG score >5)

• Upper lung infection.

• Liver or kidney function disorder